Drugmakers are slow to prove medicines that got a fast track to market really work

Stalled confirmatory trials and lax enforcement plague the Food and Drug Administration's accelerated approval pathway for pharmaceuticals that target urgent medical needs.

Related Keywords

Washington ,District Of Columbia ,United States ,Virginia ,Phoenix ,Arizona ,Rockville ,Missouri ,Ron Wyden ,Phil Mccartin ,Kristi Alcayaga ,Allison Parks ,Robert Califf ,J Scott Applewhite ,Jacqueline Corrigan Curay ,Mikkael Sekeres ,Aaron Kesselheim ,Rachel Sherman ,Francesco Tallarico ,Michaelb Thomas ,Frank Young ,Jovelle Tamayo ,Los Angele ,Covis Pharma ,Gregg Gonsalves ,Michael Alcayaga ,Lorraine Heidke Mccartin ,Walmart ,Genentech ,National Institutes Of Health ,Harvard Medical School ,Bonds ,Sylvester Cancer Center At University Of Miami ,Program On Regulation ,Drug Administration In Rockville ,Government Accountability Office ,National Institutes ,Accelerated Approval Pathway ,Los Angele Santa Monica ,Drug Administration ,Drug Evaluation ,New England ,Suzanne Kreiter ,Boston Globe ,Sylvester Cancer Center ,